A new study into the common type 2 diabetes drug sitaglipti, which is sold as Januvia, is investigating whether it could reduce levels of blood sugar in patients suffering from type 1 diabetes .
With a recent study indicating that the drug could have similar effects in those with type 1 diabetes as it does for those with the type 2 version of the metabolic condition, it is hoped that successful piloting could lead to it being a effective alternative for those wanting to improve the management of their type 1 diabetes.
The new trial, by Satish Garg of the University of Colorado, showed that Januvia, a DPP-4 inhibitor taken once a day, helped to reduce blood sugar levels and HbA1C, as well as lowering the amount of insulin needed by the patients. DPP-4 inhibitors are a type of drug that is normally used by people with type 2 diabetes.
The researchers now plan a follow-up four-month trial involving 120 people with type 1 diabetes to see if Januvia can improve overall glucose control, and potentially reduce post-meal glucose levels . People with type 1 diabetes often experience increases in post-meal glucose levels, which lead to a greater need for insulin.
However, there are still concerns that there may be a danger for people with type 1 diabetes using such a drug intended for those with type 2 diabetes, as the risks have not yet been fully determined.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…